{"commentary":{"count":15,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":9,"youtube":5,"podcast":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03606577\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"IFM 2018-04","nct_id":"NCT03606577","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=ifm-2018-04-nct03606577. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"IFM 2018-04","arms":[{"description":null,"label":"Carfilzomib, Daratumumab, Lenalidomide and Dexaméthasone","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-11-08","type":"ESTIMATED"},"conditions":["Multiple Myeloma"],"enrollment":{"count":50,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Carfilzomib","type":"DRUG"},{"name":"Daratumumab","type":"DRUG"},{"name":"Lenalidomide","type":"DRUG"},{"name":"Dexamethasone","type":"DRUG"}],"last_update":"2021-04-28","lead_sponsor":"Nantes University Hospital","official_title":"An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients: a Phase II Study of the Intergroupe Francophone du Myélome \"IFM 2018-04\"","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2022-02-08","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Percentage of patients receiving the second Autologous Stem Cell Transplant","timeFrame":"15 months"}],"references":[{"citation":"Touzeau C, Perrot A, Hulin C, Manier S, Macro M, Chretien ML, Karlin L, Escoffre M, Jacquet C, Tiab M, Leleu X, Avet-Loiseau H, Jobert A, Planche L, Corre J, Moreau P. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma. Blood. 2024 May 16;143(20):2029-2036. doi: 10.1182/blood.2023023597.","pmid":"38394666","type":"DERIVED"},{"citation":"Pawlyn C. High-risk myeloma: a challenge to define and to determine the optimal treatment. Lancet Haematol. 2021 Jan;8(1):e4-e6. doi: 10.1016/S2352-3026(20)30361-6. Epub 2020 Dec 22. No abstract available.","pmid":"33357481","type":"DERIVED"}],"start_date":{"date":"2019-07-30","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients","url":"https://clinicaltrials.gov/study/NCT03606577"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/ifm-2018-04-nct03606577"}